急性肾损伤亚表型的鉴定:不同分子特征及对血管加压素治疗的反应
该研究在两组危重急性肾损伤患者(发现组n=794,复制组n=425)中应用潜在类别分析,识别出两种急性肾损伤亚表型(AKI-SP1和AKI-SP2),并在VASST试验(n=271)中检验治疗反应差异。AKI-SP2的7天肾脏未恢复风险和28天死亡率均高于AKI-SP1,且亚表型对不良临床结局的区分能力优于KDIGO分期。在VASST中,血管加压素相比去甲肾上腺素改善AKI-SP1患者的90天死亡率(27% vs 46%,P=0.02),但在AKI-SP2中无显著差异(45% vs 49%,P=0.99),交互作用P=0.05。作者认为识别急性肾损伤亚表型可能改善风险预后评估,并可能有助于临床试验的预测性富集。
要点
- 在危重急性肾损伤患者中,潜在类别分析识别出两种亚表型(AKI-SP1和AKI-SP2),AKI-SP2的7天肾脏未恢复风险和28天死亡率高于AKI-SP1。
- 亚表型对不良临床结局的区分能力优于KDIGO的急性肾损伤分期。
- 包含内皮功能障碍和炎症标志物的三变量模型可准确判定亚表型归属(C统计量0.92)。
- 在VASST中,血管加压素相比去甲肾上腺素改善AKI-SP1的90天死亡率(27% vs 46%,P=0.02),AKI-SP2无显著差异(45% vs 49%,P=0.99),交互作用P=0.05。
- 作者认为识别急性肾损伤亚表型可能改善风险预后评估,并可能有助于临床试验的预测性富集。
适用人群与场景
- 危重急性肾损伤患者,包括发现组(n=794)和复制组(n=425),以及VASST试验中的急性肾损伤患者(n=271)。
- 所有人群中急性肾损伤均使用血清肌酐和尿量定义。
诊断标准与关键阈值
- 急性肾损伤使用血清肌酐和尿量定义。
- 亚表型由潜在类别分析确定,三变量模型(包含内皮功能障碍和炎症标志物)的C统计量为0.92。
处置流程与药物剂量
- 在VASST中,血管加压素与去甲肾上腺素比较:AKI-SP1的90天死亡率分别为27%和46%(P=0.02);AKI-SP2的90天死亡率分别为45%和49%(P=0.99);交互作用P=0.05。
研究设计与关键结果
- 研究类型:潜在类别分析,在发现组(n=794)和复制组(n=425)危重急性肾损伤患者中独立进行,随后将分类模型应用于VASST(n=271)以确定治疗反应差异。
- 两种亚表型的潜在类别分析模型在发现组(P=0.004)和复制组(P=0.004)中拟合最佳。
- AKI-SP2相对于AKI-SP1的7天肾脏未恢复风险和28天死亡率更高。
- 亚表型对不良临床结局风险的区分优于KDIGO急性肾损伤分期。
- 三变量模型(包含内皮功能障碍和炎症标志物)准确判定亚表型归属,C统计量0.92。
- 在VASST中,血管加压素相比去甲肾上腺素与AKI-SP1的90天死亡率改善相关(27% vs 46%,P=0.02),AKI-SP2无显著差异(45% vs 49%,P=0.99),交互作用P=0.05。
证据类型、等级与局限
- 证据类型:潜在类别分析研究,结合VASST试验数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为识别急性肾损伤亚表型可能改善风险预后评估,并可能有助于临床试验的预测性富集。
- 在VASST中,血管加压素相比去甲肾上腺素与AKI-SP1的90天死亡率改善相关,但AKI-SP2无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Currently, no safe and effective pharmacologic interventions exist for acute kidney injury (AKI). One reason may be that heterogeneity exists within the AKI population, thereby hampering the identification of specific pathophysiologic pathways and therapeutic targets.
OBJECTIVE: The aim of this study was to identify and test whether AKI subphenotypes have prognostic and therapeutic implications.
METHODS: First, latent class analysis methodology was applied independently in two critically ill populations (discovery [n = 794] and replication [n = 425]) with AKI. Second, a parsimonious classification model was developed to identify AKI subphenotypes. Third, the classification model was applied to patients with AKI in VASST (Vasopressin and Septic Shock Trial; n = 271), and differences in treatment response were determined. In all three populations, AKI was defined using serum creatinine and urine output.
MEASUREMENTS AND MAIN RESULTS: A two-subphenotype latent class analysis model had the best fit in both the discovery (P = 0.004) and replication (P = 0.004) AKI groups. The risk of 7-day renal nonrecovery and 28-day mortality was greater with AKI subphenotype 2 (AKI-SP2) relative to AKI subphenotype 1 (AKI-SP1). The AKI subphenotypes discriminated risk for poor clinical outcomes better than the Kidney Disease: Improving Global Outcomes stages of AKI. A three-variable model that included markers of endothelial dysfunction and inflammation accurately determined subphenotype membership (C-statistic 0.92). In VASST, vasopressin compared with norepinephrine was associated with improved 90-day mortality in AKI-SP1 (27% vs. 46%, respectively; P = 0.02), but no significant difference was observed in AKI-SP2 (45% vs. 49%, respectively; P = 0.99) and the P value for interaction was 0.05.
CONCLUSIONS: This analysis identified two molecularly distinct AKI subphenotypes with different clinical outcomes and responses to vasopressin therapy. Identification of AKI subphenotypes could improve risk prognostication and may be useful for predictive enrichment in clinical trials.
参考来源
- Bhatraju PK, Zelnick LR, Herting J, et al. Identification of Acute Kidney Injury Subphenotypes with Differing Molecular Signatures and Responses to Vasopressin Therapy. Am J Respir Crit Care Med. 2019. PMID: 30334632. doi:10.1164/rccm.201807-1346OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。